Development of macromolecular prodrug for rheumatoid arthritis

Advanced Drug Delivery Reviews

Volumn 64, Issue 12, 2012, Pages 1205-1219

  Yuan, Fang ^a   Quan, Ling dong ^a   Cui, Liao ^b   Goldring, Steven R ^c   Wang, Dong ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Drug delivery; ELVIS; Macromolecular prodrug; Rheumatoid arthritis; Targeting inflammation

Indexed keywords

ADVERSE SIDE EFFECTS; ARTHRITIC JOINTS; AUTOIMMUNE DISEASE; ELVIS; IMMUNE SYSTEMS; IMMUNOREGULATION; INFLAMMATORY DISEASE; INTERLEUKIN-6; INTRACELLULAR SIGNALING PATHWAYS; MULTIPLE CELL TYPES; PLAUSIBLE MECHANISMS; POTENTIAL BENEFITS; PRODRUGS; RATIONAL DESIGN; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNALING PATHWAYS; SYNOVIAL INFLAMMATION; TARGETING INFLAMMATION; THERAPEUTIC AGENTS; THERAPEUTIC STRATEGY; TUMOR NECROSIS FACTORS; VASCULATURE;

DISEASES; DRUG DELIVERY; DRUG INTERACTIONS; PATHOLOGY; TISSUE;

MACROMOLECULES;

ALBUMIN; ARGINYLGLYCYLASPARTIC ACID; BIOTIN; DEXAMETHASONE; DEXTRAN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HUMAN SERUM ALBUMIN; HYDROCORTISONE; LIPOSOME; MACROGOL; MACROMOLECULAR PRODRUG; MATRIX METALLOPROTEINASE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PEGAMOTECAN; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE]; POLYAMIDOAMINE; POVIDONE; PRODRUG; UNCLASSIFIED DRUG;

ADRENAL SUPPRESSION; ANTIINFLAMMATORY ACTIVITY; BRAIN TOXICITY; CATARACT; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; DRUG TARGETING; GASTROINTESTINAL HEMORRHAGE; GLAUCOMA; HUMAN; IMMUNE DEFICIENCY; INFLAMMATORY DISEASE; LIVER TOXICITY; LOW DRUG DOSE; MACROMOLECULE; MUSCLE ATROPHY; MYOPATHY; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PEPTIC ULCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERIZATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN ATROPHY; SKIN TOXICITY; STOMACH ULCER; STOMATITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INFLAMMATION; MACROMOLECULAR SUBSTANCES; PRODRUGS; SIGNAL TRANSDUCTION;

EID: 84865278791     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.03.006     Document Type: Review

References (114)

1. Quan L.D., Thiele G.M., Tian J., Wang D. The development of novel therapies for rheumatoid arthritis. Expert Opin. Ther. Pat. 2008, 18:723-738.
2. Liu X.M., Quan L.D., Tian J., Alnouti Y., Fu K., Thiele G.M., Wang D. Synthesis and evaluation of a well-defined HPMA copolymer-dexamethasone conjugate for effective treatment of rheumatoid arthritis. Pharm. Res. 2008, 25:2910-2919.
3. Gabriel S.E. The epidemiology of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 2001, 27:269-281.
4. Allaire S., Wolfe F., Niu J., Lavalley M.P. Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US. Arthritis Rheum. 2008, 59:474-480.
5. Gonzalez A., Maradit K.H., Crowson C.S., Nicola P.J., Davis J.M., Therneau T.M., Roger V.L., Gabriel S.E. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum. 2007, 56:3583-3587.
6. Barrera P., Blom A., van Lent P.L., van Bloois L., Beijnen J.H., van Rooijen N., de Waal Malefijt M.C., van de Putte L.B., Storm G., van den Berg W.B. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum. 2000, 43:1951-1959.
7. Richards P., Williams B., Williams A. Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate. Rheumatology 2001, 40:978-987.
8. Metselaar J.M., van den Berg W.B., Holthuysen A.E., Wauben M.H., Storm G., van Lent P.L. Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II athritis. Ann. Rheum. Dis. 2004, 63:348-353.
9. Rauchhaus U., Kinne R.W., Pohlers D., Wiegand S., Wölfert A., Gajda M., Bräuer R., Panzner S. Targeted delivery of liposomal dexamethasone phosphate to the spleen provides a persistent therapeutic effect in rat antigen-induced arthritis. Ann. Rheum. Dis. 2009, 68:1933-1934.
10. Rauchhaus U., Schwaiger F., Panzner S. Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatment. Arthritis Res. Ther. 2009, 11:R190.
11. Hofkens W., Storm G., van den Berg W.B., van Lent P.L. Liposomal targeting of glucocorticoids to the inflamed synovium inhibits cartilage matrix destruction during murine antigen-induced arthritis. Int. J. Pharm. 2011, 416:486-492.
12. van den Hoven J.M., Van Tomme S.R., Metselaar J.M., Nuijen B., Beijnen J.H., Storm G. Liposomal drug formulations in the treatment of rheumatoid arthritis. Mol. Pharm. 2011, 8:1002-1015.
13. Henson P.M. Dampening inflammation. Nat. Immunol. 2005, 6:1179-1181.
14. Koch A.E. Angiogenesis as a target in rheumatoid arthritis. Ann. Rheum. Dis. 2003, 62(Suppl. 2):ii60-ii67.
15. Levick J.R. Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis Rheum. 1981, 24:1550-1560.
16. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 1986, 46:6387-6392.
17. Zhang Q., Lu Y., Proulx S.T., Guo R., Yao Z., Schwarz E.M., Boyce B.F., Xing L. Increased lymphangiogenesis in joints of mice with inflammatory arthritis. Arthritis Res. Ther. 2007, 9:R118.
18. Guo R., Zhou Q., Proulx S.T., Wood R., Ji R.C., Ritchlin C.T., Pytowski B., Zhu Z., Wang Y.J., Schwarz E.M., Xing L. Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis. Arthritis Rheum. 2009, 60:2666-2676.
19. Wang D., Miller S.C., Sima M., Parker D., Buswell H., Goodrich K.C., Kopečková P., Kopeček J. The arthrotropism of macromolecules in adjuvant-induced arthritis rat model: a preliminary study. Pharm. Res. 2004, 21:1741-1749.
20. Wunder A., Müller-Ladner U., Stelzer E.H., Funk J., Neumann E., Stehle G., Pap T., Sinn H., Gay S., Fiehn C. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J. Immunol. 2003, 170:4793-4801.
21. Liu X.M., Quan L.D., Tian J., Laquer F.C., Ciborowski P., Wang D. Syntheses of click PEG-dexamethasone conjugates for the treatment of rheumatoid arthritis. Biomacromolecules 2010, 11:2621-2628.
22. Gaspar R., Duncan R. Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv. Drug Deliv. Rev. 2009, 61:1220-1231.
23. Hawkey C., Kahan A., Steinbrück K., Alegre C., Baumelou E., Bégaud B., Dequeker J., Isomäki H., Littlejohn G., Mau J., Papazoglou S. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br. J. Rheumatol. 1998, 37:937-945.
24. Gallo J.M., Gall E.P., Gillespie W.R., Albert K.S., Perrier D. Ibuprofen kinetics in plasma and synovial fluid of arthritic patients. J. Clin. Pharmacol. 1986, 26:65-70.
25. Mäkelä A.L., Lempiäinen M., Ylijoki H. Ibuprofen levels in serum and synovial fluid. Scand. J. Rheumatol. Suppl. 1981, 39:15-17.
26. Larsen C.S., Johanson M.S., Harboe E.S., Kurtzhales P.A., Olesen H.P.E. High molecular prodrug derivatives of anti-inflammatory drugs 1989, EP0331471A1.
27. Pan H., Kopečková P., Liu J., Wang D., Miller S.C., Kopeček J. Stability in plasmas of various species of HPMA copolymer-PGE1 conjugates. Pharm. Res. 2007, 24:2270-2280.
28. Montesinos M.C., Yap J.S., Desai A., Posadas I., McCrary C.T., Cronstein B.N. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum. 2000, 43:656-663.
29. Fiehn C., Neumann E., Wunder A., Krienke S., Gay S., Müller-Ladner U. Methotrexate (MTX) and albumin coupled with MTX (MTX-HSA) suppress synovial fibroblast invasion and cartilage degradation in vivo. Ann. Rheum. Dis. 2004, 63:884-886.
30. Fiehn C., Kratz F., Sass G., Müller-Ladner U., Neumann E. Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis. Ann. Rheum. Dis. 2008, 67:1188-1191.
31. Russell-Jones G. Application of biotin-mediated targeting 2004, WO/2004/045647A1.
32. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 2008, 132:171-183.
33. Stehle G., Sinn H., Wunder A., Schrenk H.H., Schütt S., Maier-Borst W., Heene D.L. The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats. Anticancer Drugs 1997, 8:677-685.
34. Hartung G., Stehle G., Sinn H., Wunder A., Schrenk H.H., Heeger S., Kränzle M., Edler L., Frei E., Fiebig H.H., Heene D.L., Maier-Borst W., Queisser W. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society. Clin. Cancer Res. 1999, 5:753-759.
35. Bolling C., Graefe T., Lübbing C., Jankevicius F., Uktveris S., Cesas A., Meyer-Moldenhauer W.H., Starkmann H., Weigel M., Burk K., Hanauske A.R. Phase II study of MTX-HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma. Invest. New Drugs 2006, 24:521-527.
36. Wilkinson P., Jeremy R., Brooks F.P., Hollander J.L. The mechanism of hypoalbuminemia in rheumatoid arthritis. Ann. Intern. Med. 1965, 63:109-114.
37. Ballantyne F.C., Fleck A., Dick W.C. Albumin metabolism in rheumatoid arthritis. Ann. Rheum. Dis. 1971, 30:265-270.
38. Lee E.S., Na K., Bae Y.H. Super pH-sensitive multifunctional polymeric micelle. Nano Lett. 2005, 5:325-329.
39. Chen S., Zhao X., Chen J., Chen J., Kuznetsova L., Wong S.S., Ojima I. Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. Bioconjug. Chem. 2010, 21:979-987.
40. Chau Y., Tan F.E., Langer R. Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX. Bioconjug. Chem. 2004, 15:931-941.
41. Davies B., Miles D.W., Happerfield L.C., Naylor M.S., Bobrow L.G., Rubens R.D., Balkwill F.R. Activity of type-IV collagenases in benign and malignant breast disease. Br. J. Cancer 1993, 67:1126-1131.
42. Hamdy F.C., Fadlon E.J., Cottam D., Lawry J., Thurrell W., Silcocks P.B., Anderson J.B., Williams J.L., Rees R.C. Matrix metalloproteinase-9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br. J. Cancer 1994, 69:177-182.
43. Levy A.T., Cioce V., Sobel M.E., Garbisa S., Grigioni W.F., Liotta L.A., Stetlerstevenson W.G. Increased expression of the Mr 72, 000 type-IV collagenase in human colonic adenocarcinoma. Cancer Res. 1991, 51:439-444.
44. Naylor M.S., Stamp G.W., Davies B.D., Balkwill F.R. Expression and activity of MMPs and their regulators in ovarian-cancer. Int. J. Cancer 1994, 58:50-56.
45. Davies B., Waxman J., Wasan H., Abel P., Williams G., Krausz T., Neal D., Thomas D., Hanby A., Balkwill F. Levels of matrix metalloproteases in bladder-cancer correlate with tumor grade and invasion. Cancer Res. 1993, 53:5365-5369.
46. Derrico A., Garbisa S., Liotta L.A., Castronovo V., Stetlerstevenson W.G., Grigioni W.F. Augmentation of type-IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast-carcinoma progression. Mod. Pathol. 1991, 4:239-246.
47. Burrage P.S., Mix K.S., Brinckerhoff C.E. Matrix metalloproteinases: role in arthritis. Front. Biosci. 2006, 11:529-543.
48. Kuyvenhoven J.P., van Hoek B., Blom E., van Duijn W., Hanemaaijer R., Verheijen J.H., Lamers C., Verspaget H.W. Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various chronic liver diseases and hepatocellular carcinoma. Thromb. Haemost. 2003, 89:718-725.
49. Chandrasekar D., Sistla R., Ahmad F.J., Khar R.K., Diwan P.V. The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats. Biomaterials 2007, 28:504-512.
50. Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur. J. Pharm. Biopharm. 2009, 71:445-462.
51. Kojima C., Kono K., Maruyama K., Tkagishi T. Synthesis of polyamidoamine dendrimers having poly-(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug. Chem. 2000, 11:910-917.
52. Tsai Y.J., Hu C.C., Chu C.C., Imae T. Intrinsically fluorescent PAMAM dendrimer as gene carrier and nanoprobe for nucleic acids delivery: bioimaging and transfection study. Biomacromolecules 2011, 12:4283-4290.
53. Bosnjakovic A., Mishra M.K., Ren W., Kurtoglu Y.E., Shi T., Fan D., Kannan R.M. Poly(amidoamine) dendrimer-erythromycin conjugates for drug delivery to macrophages involved in periprosthetic inflammation. Nanomedicine 2011, 7:284-294.
54. Waite C.L., Roth C.M. PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma. Bioconjug. Chem. 2009, 20:1908-1916.
55. Majoros I.J., Thomas T.P., Mehta C.B., Baker J.R. Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J. Med. Chem. 2005, 48:5892-5899.
56. Zhang Y., Thomas T.P., Lee K.H., Li M., Zong H., Desai A.M., Kotlyar A., Huang B., Holl M.M., Baker J.R. Polyvalent saccharide-functionalized generation 3 poly(amidoamine) dendrimer-methotrexate conjugate as a potential anticancer agent. Bioorg. Med. Chem. 2011, 19:2557-2564.
57. McNerny D.Q., Kukowska-Latallo J.F., Mullen D.G., Wallace J.M., Desai A.M., Shukla R., Huang B., Banaszak Holl M.M., Baker J.R. RGD dendron bodies; synthetic avidity agents with defined and potentially interchangeable effector sites that can substitute for antibodies. Bioconjug. Chem. 2009, 20:1853-1859.
58. Koning G.A., Schiffelers R.M., Wauben M.H., Kok R.J., Mastrobattista E., Molema G., ten Hagen T.L., Storm G. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum. 2006, 54:1198-1208.
59. Matsushita N.N., Homma T., Yu S., Matsuda T., Sunahara N., Nakamura T., Tsukano M., Ratnam M., Matsuyama T. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 1999, 42:1609-1616.
60. Todoerti M., Scirè C.A., Boffini N., Bugatti S., Montecucco C., Caporali R. Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. Ann. N. Y. Acad. Sci. 2010, 1193:139-145.
61. Schäcke H., Berger M., Rehwinkel H., Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol. Cell. Endocrinol. 2007, 275:109-117.
62. Stahn C., Löwenberg M., Hommes D.W., Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol. Cell. Endocrinol. 2007, 275:71-78.
63. Timofeevski S.L., Panarin E.F., Vinogradov O.L., Nezhentsev M.V. Anti-inflammatory and antishock water-soluble polyesters of glucocorticoids with low level systemic toxicity. Pharm. Res. 1996, 13:476-480.
64. Mehvar R., Dann R.O., Hoganson D.A. Kinetics of hydrolysis of dextran-methylprednisolone succinate, a macromolecular prodrug of methylprednisolone, in rat blood and liver lysosomes. J. Control. Release 2000, 68:53-61.
65. Penugonda S., Kumar A., Agarwal H.K., Parang K., Mehvar R. Synthesis and in vitro characterization of novel dextran-methylprednisolone conjugates with peptide linkers: effects of linker length on hydrolytic and enzymatic release of methylprednisolone and its peptidyl intermediates. J. Pharm. Sci. 2008, 97:2649-2664.
66. Onishi H., Saito Y., Sasatsu M., Machida Y. Kinetic analysis of in vitro and in vivo release of prednisolone from the conjugate of glycol-chitosan and succinyl-prednisolone. Int. J. Pharm. 2011, 410:17-22.
67. Varshosaz J., Emami J., Tavakoli N., Fassihi A., Minaiyan M., Ahmadi F., Dorkoosh F. Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis. Int. J. Pharm. 2009, 365:69-76.
68. Perumal O., Khandare J., Kolhe P., Kannan S., Lieh-Lai M., Kannan R.M. Effects of branching architecture and linker on the activity of hyperbranched polymer-drug conjugates. Bioconjug. Chem. 2009, 20:842-846.
69. Inapagolla R., Guru B.R., Kurtoglu Y.E., Gao X., Lieh-Lai M., Bassett D.J., Kannan R.M. In vivo efficacy of dendrimer-methylprednisolone conjugate formulation for the treatment of lung inflammation. Int. J. Pharm. 2010, 399:140-147.
70. Keely S., Ryan S.M., Haddleton D.M., Limer A., Mantovani G., Murphy E.P., Colgan S.P., Brayden D.J. Dexamethasone-pDMAEMA polymeric conjugates reduce inflammatory biomarkers in human intestinal epithelial monolayers. J. Control. Release 2009, 135:35-43.
71. Hamidi M., Azadi A., Rafiei P. Hydrogel nanoparticles in drug delivery. Adv. Drug Deliv. Rev. 2008, 60:1638-1649.
72. Kopeček J., Bažilová H. Poly[N-(2-hydroxypropyl)methacrylamide]. I. Radical polymerization and copolymerization. Eur. Polym. J. 1973, 9:7-14.
73. Kopeček J. Controlled biodegradability of polymers-a key to drug delivery systems. Biomaterials 1984, 5:19-25.
74. Kopeček J., Kopečková P., Minko T., Lu Z. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 2000, 50:61-81.
75. Peterson C.M., Lu J.M., Sun Y., Peterson C.A., Shiah J.G., Straight R.C., Kopeček J. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl) methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Cancer Res. 1996, 3980-3985.
76. Kopeček J., Sprincl L., Lim D. New types of synthetic infusion solutions. I. Investigation of the effect of solutions of some hydrophilic polymers on blood. J. Biomed. Mater. Res. 1973, 7:179-191.
77. Ríhová B., Ulbrich K., Kopeček J., Mančal P. Immunogenicity of N-(2-hydroxypropyl)-methacrylamide copolymers-potential hapten or drug carriers. Folia Microbiol. (Praha) 1983, 28:217-227.
78. Ř;íhová B., Kopeček J., Ulbrich K., Pospíšil J., Mančal P. Effect of the chemical structure of N-(2-hydroxypropyl)methacrylamide copolymers on their ability to induce antibody formation in inbred strains of mice. Biomaterials 1984, 5:143-148.
79. Seymour L.W., Duncan R., Strohalm J., Kopeček J. Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J. Biomed. Mater. Res. 1987, 21:1341-1358.
80. Říhová B., Kopeček J., Ulbrich K., Chytrý V. Immunogenicity of N-(2-hydroxypropyl)methacrylamide copolymers. Makromol. Chem. Suppl. 1985, 9:13-24.
81. Říhová B., Kovár M. Immunogenicity and immunomodulatory properties of HPMA-based polymers. Adv. Drug Deliv. Rev. 2010, 62:184-191.
82. Říhová B. Biocompatibility and immunocompatibility of water-soluble polymers based on HPMA. Composites Part B 2007, 38:386-397.
83. Goldie I., Nachemson A. Synovial pH in rheumatoid kneejoints. I. The effect of synovectomy. Acta Orthop. Scand. 1969, 40:634-641.
84. Andersson S.E., Lexmuller K., Johansson A., Ekstrom G.M. Tissue and intracellular pH in normal periarticular soft tissue and during different phases of antigen induced arthritis in the rat. J. Rheumatol. 1999, 26:2018-2024.
85. Konttinen Y.T., Mandelin J., Li T.F., Salo J., Lassus J., Liljeström M., Hukkanen M., Takagi M., Virtanen I., Santavirta S. Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rheum. 2002, 46:953-960.
86. Konttinen Y.T., Takagi M., Mandelin J., Lassus J., Salo J., Ainola M., Li T.F., Virtanen I., Liljeström M., Sakai H., Kobayashi Y., Sorsa T., Lappalainen R., Demulder A., Santavirta S. Acid attack and cathepsin K in bone resorption around total hip replacement prosthesis. J. Bone Miner. Res. 2001, 16:1780-1786.
87. Falchuk K.H., Goetzl E.J., Kulka J.P. Respiratory gases of synovial fluids. An approach to synovial tissue circulatory-metabolic imbalance in rheumatoid arthritis. Am. J. Med. 1970, 49:223-231.
88. Levick J.R. Hypoxia and acidosis in chronic inflammatory arthritis; relation to vascular supply and dynamic effusion pressure. J. Rheumatol. 1990, 17:579-582.
89. Wang D., Miller S.C., Liu X.M., Anderson B., Wang X.S., Goldring S.R. Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. Arthritis Res. Ther. 2007, 9:R2.
90. Quan L.D., Yuan F., Liu X.M., Huang J.G., Alnouti Y., Wang D. Pharmacokinetic and biodistribution studies of N-(2-hydroxypropyl)methacrylamide copolymer-dexamethasone conjugates in adjuvant-induced arthritis rat model. Mol. Pharm. 2010, 7:1041-1049.
91. Wang D., Pechar M., Li W., Kopečková P., Brömme D., Kopeček J. Inhibition of cathepsin K with lysosomotropic macromolecular inhibitors. Biochemistry 2002, 41:8849-8859.
92. Pasut G., Veronese F.M. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv. Drug Deliv. Rev. 2009, 61:1177-1188.
93. Rowinsky E.K., Rizzo J., Ochoa L., Takimoto C.H., Forouzesh B., Schwartz G., Hammond L.A., Patnaik A., Kwiatek J., Goetz A., Denis L., McGuire J., Tolcher A.W. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3weeks in patients with advanced solid malignancies. J. Clin. Oncol. 2003, 21:148-157.
94. Funk D., Schrenk H.H., Frei E. Development of a novel polyethylene glycol-corticosteroid-conjugate with an acid-cleavable linker. J. Drug Target. 2011, 19:434-445.
95. Quan L.D., Purdue P.E., Liu X.M., Boska M.D., Lele S.M., Thiele G.M., Mikuls T.R., Dou H., Goldring S.R., Wang D. Development of a macromolecular prodrug for the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and sustained therapeutic efficacy. Arthritis Res. Ther. 2010, 12:R170.
96. Wang D., Goldring S.R. The bone, the joints and the balm of gilead. Mol. Pharm. 2011, 8:991-993.
97. Bures L., Bostík J., Motycka K., Spundová M., Rehák L. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. III. Human serum albumin-methotrexate derivative, its preparation and basic testing. Neoplasma 1988, 35:329-342.
98. Esteban N.V., Loughlin T., Yergey A.L., Zawadzki J.K., Booth J.D., Winterer J.C., Loriaux D.L. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J. Clin. Endocrinol. Metab. 1991, 72:39-45.
99. Gudbjörnsson B., Skogseid B., Oberg K., Wide L., Hällgren R. Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis. Effect of glucocorticoids. J. Rheumatol. 1996, 23:596-602.
100. Chikanza I.C., Petrou P., Kingsley G., Chrousos G., Panayi G.S. Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis Rheum. 1992, 35:1281-1288.
101. Barnes P.J. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin. Sci. (Lond.) 1998, 94:557-572.
102. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis: Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001, 44:1496-1503.
103. Dekhuijzen P.N., Decramer M. Steroid-induced myopathy and its significance to respiratory disease: a known disease rediscovered. Eur. Respir. J. 1992, 5:997-1003.
104. Stuck A.E., Minder C.E., Frey F.J. Risk of infectious complications in patients taking glucocorticosteroids. Rev. Infect. Dis. 1989, 11:954-963.
105. Sampson P.A., Brooke B.N., Winstone N.E. Biochemical confirmation of collapse due to adrenal failure. Lancet 1961, 1:1377.
106. Firestein G.S. Rheumatoid arthritis in a mouse?. Nat. Clin. Pract. Rheumatol. 2009, 5:1.
107. Hart B.A., Bank R.A., De Roos J.A., Brok H., Jonker M., Theuns H.M., Hakimi J., Te Koppele J.M. Collagen-induced arthritis in rhesus monkeys: evaluation of markers for inflammation and joint degradation. Br. J. Rheumatol. 1998, 37:314-323.
108. Vierboom M.P., Jonker M., Bontrop R.E., 't Hart B. Modeling human arthritic diseases in nonhuman primates. Arthritis Res. Ther. 2005, 7:145-154.
109. Bolon B., Stolina M., King C., Middleton S., Gasser J., Zack D., Feige U. Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy. J. Biomed. Biotechnol. 2011, 2011:569068.
110. Sternberg E.M., Hill J.M., Chrousos G.P., Kamilaris T., Listwak S.J., Gold P.W., Wilder R.L. Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc. Natl. Acad. Sci. 1989, 86:2374-2378.
111. Kiely P.D., Bland J.M., Joseph A.E., Mortimer P.S., Bourke B.E. Upper limb lymphatic function in inflammatory arthritis. J. Rheumatol. 1995, 22:214-217.
112. Kiely P.D., Joseph A.E., Mortimer P.S., Bourke B.E. Upper limb lymphedema associated with polyarthritis of rheumatoid type. J. Rheumatol. 1994, 21:1043-1045.
113. Ren K., Purdue P.E., Burton L., Quan L.D., Fehringer E.V., Thiele G.M., Goldring S.R., Wang D. Early detection and treatment of wear particle-induced inflammation and bone loss in a mouse calvarial osteolysis model using HPMA copolymer conjugates. Mol. Pharm. 2001, 8:1043-1051.
114. Lindstrom T.M., Robinson W.H. A multitude of kinases-which are the best targets in treating rheumatoid arthritis?. Rheum. Dis. Clin. North Am. 2010, 36:367-383.